BACKGROUND:
There are limited
data regarding human immunodeficiency virus (HIV) prevalence among hepatitis B
virus (HBV) or hepatitis C virus (HCV) infected individuals. The aim of this
cross-sectional study is to determine the prevalence of HBV and HCV infection
among HIV individuals;
METHODS:
A total of 409
patients (126 HBV+ and 283 HCV+) referred to the Brazilian Reference Laboratory
for Viral Hepatitis from 2010 to 2013 donated serum samples. Anti-HIV, HBsAg,
anti-HBc, anti-HBs, anti-HBcIgM, anti-HBe, HBeAg, and anti-HCV antibodies were
measured, and anti-HCV positive samples were tested for viral RNA and genotype;
RESULTS:
The anti-HIV
antibody prevalence was 10.31% and 4.59% among HBV+ and HCV+ patients,
respectively. The HCV mean (SD) viral load was log 5.14 ± 1.64 IU/mL, and
genotype I was most prevalent (163/283). Anti-HBs and anti-HBc were detected in
40% and 26% of HCV+ individuals, respectively. Among the HBV+ population, the
presence of anti-HIV antibodies was associated with male gender, marital status
(married), tattoo, sexual orientation, sexual practices (oral sex and anal
sex), history of sexually transmitted diseases (STDs), history of viral
hepatitis treatment, and a sexual partner with hepatitis or HIV. For the HCV+
group, the presence of anti-HIV antibodies was associated with female gender,
marital status (married), anal intercourse, previous history of STDs, and
number of sexual partners;
CONCLUSION:
A high prevalence
of anti-HIV antibodies was found among individuals with HBV and HCV, showing
the importance of education programmes towards HIV infection among HBV- and
HCV-infected individuals.
Full article at: http://goo.gl/7pJhyw
By: Flores GL1, de Almeida AJ2, Miguel JC3, Cruz HM4, Portilho MM5, de P Scalioni L6, Marques VA7, Lewis-Ximenez LL8, Lampe E9, Melo Villar L10.
- 1Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. geane@ioc.fiocruz.br.
- 2Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. adilsonjoal@ioc.fiocruz.br.
- 3Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. julicm@ioc.fiocruz.br.
- 4Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. h.medina@ioc.fiocruz.br.
- 5Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. moyramp@ioc.fiocruz.br.
- 6Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. lescali@ioc.fiocruz.br.
- 7Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. vmarques@ioc.fiocruz.br.
- 8Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. llewis@ioc.fiocruz.br.
- 9Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. elampe@ioc.fiocruz.br.
- 10Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 210360-040, Brazil. lvillar@ioc.fiocruz.br.
- Int J Environ Res Public Health. 2016 Mar 11;13(3). pii: E314. doi: 10.3390/ijerph13030314.
More at: https://twitter.com/hiv insight
No comments:
Post a Comment